Roche, Eli Lilly’s Alzheimer’s blood test gets FDA clearance

FDA Clears Roche–Lilly Blood Panel for Early Alzheimer’s Detection

Healfromzero.com – The Food and Drug Administration on Monday granted clearance to a new biomarker blood assay developed jointly by Roche and Eli Lilly, marking another step toward making Alzheimer’s screening accessible outside specialized memory clinics. The test, branded Elecsys pTau217, is designed for adults aged 55 and older who are already showing signs of cognitive decline. By measuring levels of a specific tau protein in a standard blood draw, it helps clinicians gauge whether Alzheimer’s-related pathology is likely present in the brain or unlikely to be.

The clearance follows a European regulatory approval that landed in May, giving the assay a transatlantic footprint within months. Roche emphasized that the test is compatible with more than 4,500 laboratory analyzers already deployed across American hospitals and reference labs, a logistical advantage the company framed as a pathway to wider patient access. Two of the nation’s largest clinical-laboratory networks, Labcorp and Quest Diagnostics, confirmed they intend to incorporate the assay into their existing menus, which would place it within reach of primary-care physicians who order routine bloodwork.

Where the Test Sits in a Crowded Diagnostic Landscape

The FDA decision arrives amid a rapid acceleration of Alzheimer’s-specific diagnostics. In 2025, Fujirebio’s Lumipulse became the first blood-based assay to receive FDA clearance for aiding Alzheimer’s assessment. Roche and Lilly’s own Elecsys pTau181 panel, which tracks a different tau isoform, earned its green light the following year. Most recently, the agency cleared C2N Diagnostics’ Precivity AD2 test just last week. The clustering of approvals signals that regulators now view plasma biomarker panels as a viable complement to traditional imaging and cerebrospinal-fluid procedures.

Historically, confirming Alzheimer’s pathology required positron-emission tomography scans or lumbar punctures—procedures that are costly, invasive, and available only at academic medical centers. Blood-based assays measuring phosphorylated tau 217, commonly abbreviated p-tau217, offer a far less burdensome entry point. The scientific rationale is well established: elevated p-tau217 in circulation tracks closely with the accumulation of beta-amyloid plaques in brain tissue, often decades before any overt memory loss appears. In some individuals, amyloid deposition is already underway in their 30s or 40s, long before clinical symptoms emerge.

What the Biomarker Actually Tells a Clinician

As amyloid plaques proliferate, they provoke neuroinflammation and disrupt synaptic signaling. Over time, tangled tau protein accumulates inside neurons, eventually causing those cells to collapse and die. The relationship, however, is not perfectly one-to-one. Rachel Buckley, an associate professor of neurology at Harvard Medical School, explained earlier this year that p-tau217 levels “strongly predict” amyloid buildup, but cautioned that the correlation is probabilistic rather than deterministic. In certain conditions such as frontal lobe dementia, where executive function deteriorates before memory, tau tangles can form without significant amyloid involvement. Conversely, some individuals carry high amyloid loads yet never progress to frank dementia, and the mere presence of tau does not guarantee later cognitive impairment.

Roche stressed that Elecsys pTau217 is not intended as a standalone diagnostic instrument. Results must be interpreted in concert with clinical history, neuropsychological testing, and, where appropriate, imaging or other laboratory data.

Expert Caution on Predictive Limits

Dr. Richard Isaacson, director of research at the Institute for Neurodegenerative Diseases in Florida and a long-time Alzheimer’s prevention investigator, offered a measured assessment in an email sent Monday.

“Single ‘Alzheimer’s blood tests’ can be fraught with challenges, and this new test is no different. Just like when a doctor orders a cholesterol test, do they ever order only 1 test? No — they order a panel of tests and that is the strategy that I advocate for to minimize confusion and improve clinical diagnostic and risk prediction accuracy.”

Isaacson acknowledged that the assay carries a “sufficient negative predictive value,” meaning a negative result reasonably rules out Alzheimer’s pathology. He was less sanguine about the positive side, noting that the “positive predictive value is not great” and that false-positive results remain a practical concern, particularly because the test also yields indeterminate classifications. Pre-analytical variables—improper sample handling, concurrent kidney disease, or active viral infection—can muddy interpretation and introduce noise into an already complex clinical picture.

Rather than deploying p-tau217 and companion amyloid assays as one-shot diagnostic verdicts, Isaacson uses them longitudinally to monitor how patients respond to therapeutic and lifestyle interventions. In his experience, sustained improvements in diet, physical activity, sleep hygiene, and social engagement—paired with pharmacologic management of insulin resistance, cholesterol, and vascular risk factors—have produced measurable reductions in both amyloid and tau biomarker levels among committed patients.

The Prevention Angle

The broader public-health stakes extend well beyond earlier diagnosis. Laura Nisenbaum, interim chief science officer at the Alzheimer’s Drug Discovery Foundation, told CNN earlier this year that emerging evidence suggests up to 45 percent of dementia cases may be preventable through sustained lifestyle modification, including regular exercise, dietary optimization, cognitive training, social participation, and active management of vascular and metabolic risk factors. If that figure holds across larger cohorts, the availability of inexpensive, repeatable blood biomarkers could transform primary-care workflows: physicians would be able to track whether a patient’s preventive efforts are actually lowering biological risk, turning a once-terminal diagnosis into a manageable, modifiable condition.

Roche has not yet disclosed a list price for Elecsys pTau217. As Labcorp and Quest Diagnostics integrate the assay into their panels over coming months, the question will shift from regulatory feasibility to real-world uptake—how often primary-care physicians will order it, how results will be contextualized in electronic health records, and whether the test ultimately shortens the years-long gap between silent brain pathology and clinical intervention.